[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-insipidus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-insipidus":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,79,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100544433","phase-2-a-study-of-lower-radiotherapy-dose-to-treat-children-with-cns-germinoma-100544433",false,"NCT06368817","A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma","A Phase II Trial Evaluating Chemotherapy Followed by Response-Based Reduced Radiation Therapy for Patients With Central Nervous System Germinomas","Inclusion Criteria:\n\n* Patients must be ≥ 3 years and \\\u003C 30 years at the time of study enrollment\n* Patients must be newly-diagnosed primary localized germinoma of the suprasellar and\u002For pineal region by pathology and\u002For serum and\u002For CSF hCGbeta 5-50 mIU\u002FmL AND institutional normal AFP (or ≤ 10 ng\u002FmL if no institutional normal exists), including tumors with contiguous ventricular or unifocal parenchymal extension. No histologic confirmation required\n* Patients with EITHER (A) bifocal (pineal + suprasellar) involvement OR (B) pineal lesion with diabetes insipidus (DI) AND hCGbeta ≤ 100 mIU\u002FmL in serum and\u002For CSF AND institutional normal AFP (or ≤ 10 ng\u002FmL if no institutional normal exists) in both serum and CSF. No histologic confirmation required\n* Patients with hCGbeta 51-100 mIU\u002FmL in serum and\u002For CSF and institutional normal AFP (or ≤ 10 ng\u002FmL if no institutional normal exists) in both serum and CSF. Histologic confirmation of germinoma IS required\n* Patients with germinoma of the basal ganglia and or\u002Fthalamic primary sites are eligible\n* Patients with metastatic germinoma including non-contiguous disease or distant disease in the brain, ventricles, or spine are eligible\n* Patients with germinoma admixed with mature teratoma are eligible\n* Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients \\> 16 years of age and Lansky for patients ≤ 16 years of age\n* Patients must have eligibility confirmed by Rapid Central Imaging Review performed on APEC14B1-CNS\n* Imaging studies must be obtained within 31 days prior to study enrollment and start of protocol therapy. (Note: for patients that have had surgery and post-operative imaging performed, it is the post-operative MRI that must be obtained within 31 days prior to enrollment.)\n* Patients must have a cranial magnetic resonance imaging (MRI) with and without gadolinium at diagnosis\u002Fprior to enrollment. If surgical resection is performed, patients must have pre-operative and post-operative brain MRI with and without gadolinium. The post-operative brain MRI should be obtained within 72 hours of surgery. If patient has a biopsy only, post-operative brain MRI is recommended but not required\n* Patients must have a spine MRI with gadolinium obtained at diagnosis\u002Fprior to enrollment\n* Patients must be enrolled, and protocol therapy must begin, no later than 31 days after definitive surgery or clinical diagnosis, whichever is later\n* Patients must have eligibility confirmed by Rapid Central Tumor Marker Review performed on APEC14B1-CNS\n* Lumbar CSF must be obtained prior to study enrollment unless medically contraindicated. If a patient undergoes surgery and lumbar CSF cytology cannot be obtained at the time of surgery, then it should be performed at least 10 days following surgery and prior to study enrollment. False positive cytology can occur within 10 days of surgery. Of note, lumbar CSF should not be performed prior to obtaining spine MRI, as this can make interpretation of the spine MRI less clear\n* Patients must have CSF tumor markers obtained prior to study enrollment unless medically contraindicated. Ventricular CSF obtained at the time of CSF diversion procedure (if performed) is acceptable for tumor markers but lumbar CSF is preferred. In case CSF diversion and biopsy\u002Fsurgery are combined, CSF tumor markers should be collected first. Ideally serum and CSF tumor markers should be collected at the same time and processed without delay\n* For patients with solid tumors: Peripheral absolute neutrophil count (ANC) \\>= 1000\u002FuL (Must be performed within 7 days prior to enrollment unless otherwise indicated)\n* For patients with solid tumors: Platelet count \\>= 100,000\u002FuL (transfusion independent) (Must be performed within 7 days prior to enrollment unless otherwise indicated)\n* For patients with solid tumors: Hemoglobin \\>= 8.0 g\u002FdL (may receive red blood cell \\[RBC\\] transfusions) (Must be performed within 7 days prior to enrollment unless otherwise indicated)\n* For pediatric patients (age 3-17 years): A serum creatinine based on age\u002Fsex as follows (Must be performed within 7 days prior to enrollment unless otherwise indicated):\n\n  * Age: 3 to \\\u003C 6 years; maximum serum creatinine (mg\u002FdL): 0.8 (male); 0.8 (female)\n  * Age: 6 to \\\u003C 10 years; maximum serum creatinine (mg\u002FdL): 1 (male); 1 (female)\n  * Age: 10 to \\\u003C 13 years; maximum serum creatinine (mg\u002FdL): 1.2 (male); 1.2 (female)\n  * Age: 13 to \\\u003C 16 years; maximum serum creatinine (mg\u002FdL): 1.5 (male); 1.4 (female)\n  * Age: ≥ 17 years; maximum serum creatinine (mg\u002FdL): 1.7 (male); 1.4 (female) OR a 24-hour urine creatinine clearance ≥ 70 mL\u002Fmin\u002F1.73 m\\^2 OR a glomerular filtration rate (GFR) ≥ 50 mL\u002Fmin\u002F1.73 m\\^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard).\n  * Note: Estimated GFR (eGFR) from serum or plasma creatinine, cystatin C or other estimates are not acceptable for determining eligibility.\n  * For adult patients (age 18 years or older) (Must be performed within 7 days prior to enrollment unless otherwise indicated):\n\n    * Creatinine clearance ≥ 70 mL\u002Fmin, as estimated by the Cockcroft and Gault formula or a 24-hour urine collection. The creatinine value used in the calculation must have been obtained within 28 days prior to registration. Estimated creatinine clearance is based on actual body weight\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age (Must be performed within 7 days prior to enrollment unless otherwise indicated)\n* Serum glutamic-pyruvic transaminase (SGPT) (alanine transaminase \\[ALT\\]) ≤ 135 U\u002FL (Must be performed within 7 days prior to enrollment unless otherwise indicated)\n\n  * Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U\u002FL\n* No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \\> 94% if there is clinical indication for determination\n* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled\n* CNS toxicity =\\\u003C grade 2\n* Patients must not be in status epilepticus, coma or assisted ventilation prior to study enrollment\n* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load are eligible for this study\n\nExclusion Criteria:\n\n* Patients with any of the following malignant pathological elements are not eligible:\n\n  * Endodermal sinus (yolk sac)\n  * Embryonal carcinoma, choriocarcinoma\n  * Malignant\u002Fimmature teratoma and mixed germ cell tumor (GCT) (i.e., may include some germinoma)\n* Patients with only mature teratoma upon tumor sampling at diagnosis and negative tumor markers are not eligible\n* Patients who have received any prior tumor-directed therapy for their diagnosis of germinoma other than surgical intervention and corticosteroids are not eligible\n* Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential.\n\n  * Note: Serum and urine pregnancy tests may be falsely positive due to HCGbeta-secreting germ cell tumors. Ensure the patient is not pregnant by institutional standards\n* Lactating females who plan to breastfeed their infants\n* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation\n* All patients and\u002For their parents or legal guardians must sign a written informed consent\n* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met","ALL","3 Years","29 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \\& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Researchers want to see if lowering the dose of standard radiotherapy (RT) after chemotherapy can help get rid of CNS germinomas with fewer long-term side effects.",[27,28,29,30,31,32],"Basal Ganglia Germinoma","Diabetes Insipidus","Germinoma","Pineal Region Germinoma","Suprasellar Germinoma","Thalamic Germinoma","RECRUITING","2026-04-28",{"date":36,"type":37},"2026-05-04","ACTUAL",{"date":39,"type":37},"2024-10-22",{"date":41,"type":21},"2033-11-04",{"name":43,"class":44},"Children's Oncology Group","NETWORK",109,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100620718","plasma-oxytocin-response-to-oral-estrogens-in-healthy-controls-and-avp-deficiency-100620718","NCT07361263","Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency","Plasma Oxytocin in Response to Oral Estradiol Valerate and Ethinylestradiol in Healthy Controls and Patients With AVP-Deficiency","PHOENIX","Inclusion Criteria:\n\nPart 1\n\n1. Adult healthy controls\n2. No medication (including hormonal contraception)\n3. Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months\n\nPart 2\n\n1. Confirmed diagnosis of AVP-Deficiency\n2. Age ≥ 18 years\n3. Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months or in the case of hormone replacement therapy, with a 1-week pause from the respective treatment\n\nExclusion Criteria:\n\nPart 1\n\n1. Participation in a trial with investigational drugs within 30 days\n2. BMI \\>30\n3. Age \\>50\n4. Illicit substance use (except for cannabis) during the last 30 days\n5. Consumption of alcoholic beverages \\>15 drinks\u002Fweek\n6. Tobacco smoking \\>10 cigarettes\u002Fday\n7. Pregnancy and breastfeeding\n8. Hormonal contraception\n9. Migraine with and without aura\n10. Any cardiometabolic, cardiovascular, and hematological diseases (including deep vein thrombosis\u002Fpulmonary embolism and thrombophilia (DVT\u002FPE))\n11. Active liver dysfunction or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range\n12. Diagnosed chronic kidney disease (CKD) \\> grade III (GRF \\\u003C 30ml\u002Fmin)\n\nPart 2\n\n1. Participation in a trial with investigational drugs within 30 days\n2. BMI \\>30\n3. Age \\>50\n4. Illicit substance use (except for cannabis) during the last 30 days\n5. Consumption of alcoholic beverages \\>15 drinks\u002Fweek\n6. Tobacco smoking \\>10 cigarettes\u002Fday\n7. Pregnancy and breastfeeding\n8. Hormonal contraception\n9. Migraine with and without aura\n10. Any cardiometabolic, cardiovascular, and hematological diseases (including DVT\u002FPE and Thrombophilia)\n11. Active liver dysfunction or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range\n12. Diagnosed CKD \\> grade III (GRF \\\u003C 30ml\u002Fmin)",true,"18 Years","50 Years",{"count":58,"type":21},28,[60],"NA","The PHOENIX study aims to investigate whether oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans. The goal is to assess their potential as a safe diagnostic stimulation test for oxytocin deficiency, particularly in patients with arginine vasopressin (AVP) deficiency.",[63,28],"AVP Deficiency",[65,66,67],"Oxytocin","estradiol valerate","ethinylestradiol","2026-01-22",{"date":70,"type":37},"2026-01-23",{"date":72,"type":37},"2026-01-09",{"date":74,"type":21},"2027-02",{"name":76,"class":77},"University Hospital, Basel, Switzerland","OTHER",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":97,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":78},"100273617","wolfram-syndrome-and-wfs1-related-disorders-international-registry-and-clinical-study-100273617","NCT02841553","Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study","Any patient worldwide with a diagnosis of Wolfram syndrome and with access to the Internet can be enrolled in the Registry. Since the disease usually manifests in the first decade of life and tends to have an inevitably progressive course, participation of minors is important for establishing the natural course of the disease.\n\nInclusion Criteria:\n\nMajor Criteria\n\n* Diabetes mellitus \\\u003C16 yrs\n* Optic atrophy \\\u003C16 yrs\n\nMinor Criteria\n\n* Diabetes insipidus\n* Diabetes mellitus \\>16yrs\n* Optic atrophy \\>16 yrs\n* Sensorineural deafness\n* Neurological signs (ataxia, epilepsy, cognitive impairment)\n* Renal tract abnormalities (structural or functional)\n* 1 loss of function mutation in WFS1\u002FCISD2 AND\u002FOR family history of Wolfram syndrome\n\nMinimum Required\n\n* 2 major OR\n* 1 major plus 2 minor criteria OR\n* 2 pathological WFS1 or CISD2 mutations are identified\n\nOther variable suggestive evidence\n\n* Hypogonadism (males)\n* An absence of type 1 diabetes auto-antibodies\n* Bilateral cataracts\n* Psychiatric disorder\n* Gastrointestinal\n\nExclusion Criteria:\n\nInability of a patient and\u002For a guardian to obtain help with translation and thus, inability to understand questionnaire.\n\nParent, Sibs, and Spouses:\n\n\\- Parents, sibs, and spouses that are unaffected will be recruited as controls. Inclusion criterion is having the unaffected status and exclusion criterion is if the person cannot understand the Informed Consent Document.","0 Years",{"count":87,"type":21},5000,"20 Years","OBSERVATIONAL","In this study, the investigators hypothesize that studying monogenic variants with strong effect associated with severe insulin deficiency of Wolfram syndrome will provide important insights into the more complex type 1 and type 2 diabetes mellitus.\n\nAim 1. Establish and maintain a registry of patients with Wolfram syndrome. An Internet based registry will be employed to enroll participants with the clinical diagnosis of Wolfram syndrome (insulin dependent DM and bilateral OA). Clinical information regarding age of diagnosis and progression of the disease will be collated and analyzed to better define its natural history, along with potential metabolic phenotypes such as glucose intolerance of heterozygous parents and unaffected sibs.\n\nIf not already completed, blood for WFS1 sequence analysis will be obtained on the participants (parents and sibs also for control purposes) and sent to a CLIA certified lab to define the mutation. This information will benefit patient families and referring physicians by providing a genetic diagnosis and where indicated. The Wolfram Syndrome Registry will foster international collaborations to more efficiently and systematically collect Wolfram syndrome patients and their clinical and experimental data.",[92,93,94,95,28,96],"Wolfram Syndrome","Diabetes Mellitus","Optic Nerve Atrophy","Deafness","Ataxia",[98],"Endoplasmic Reticulum Stress","2025-12-19",{"date":101,"type":37},"2025-12-23",{"date":103,"type":4},"2011-07",{"date":105,"type":21},"2027-04",{"name":107,"class":77},"Washington University School of Medicine",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":130,"locationsCount":78},"100568096","phase-2-effect-of-intranasal-oxytocin-on-emotion-recognition-and-acute-psycho-social-stress-induced-cortisol-increase-in-patients-with-central-diabetes-insipidus-and-healthy-controls-100568096","NCT06676774","Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls","Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus (Arginine Vasopressin Deficiency) and Healthy Controls - the OxyMOTION-Study","OxyMOTION","Inclusion criteria healthy controls\n\n1. Adult healthy volunteers\n2. Matched for age, sex, BMI, and oestrogen replacement\u002Fmenopause\u002Fhormonal contraceptives to patients.\n3. No medication, except hormonal contraception\n\nInclusion criteria\n\n1. Adult patients with a confirmed diagnosis of AVP deficiency based on accepted criteria6\n2. Stable hormone replacement therapy for at least three months with desmopressin and, in case of additional anterior pituitary deficiencies, with the respective substitution therapies.\n\nExclusion criteria\n\n1. Participation in a trial with investigational drugs within 30 days\n2. Active substance use disorder within the last six months\n3. Consumption of alcoholic beverages \\>15 drinks\u002Fweek\n4. Current or previous psychotic disorder (e.g., schizophrenia spectrum disorder)\n5. Pregnancy and breastfeeding within the last eight weeks",{"count":117,"type":21},42,[24],"This study aims to investigate the potential beneficial effects of intranasal oxytocin compared to placebo on emotion recognition and acute psychosocial stress in patients with arginine vasopressin deficiency compared to matched healthy controls.",[121,28],"Arginine Vasopressin Deficiency",[123],"intranasal oxytocin","2025-05-22",{"date":126,"type":37},"2025-05-23",{"date":128,"type":37},"2025-05-16",{"date":74,"type":21},{"name":76,"class":77}]